May 11, 2020 / 12:34 PM / 25 days ago

BRIEF-Bluebird Bio Reports First Quarter 2020 Financial Results

May 11 (Reuters) - bluebird bio Inc:

* BLUEBIRD BIO PROVIDES OPERATIONAL AND BUSINESS UPDATE AND REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

* Q1 REVENUE ESTIMATE $7.5 MILLION — REFINITIV IBES DATA

* REVISED OPERATING PLAN ACHIEVES CASH SAVINGS OF OVER $500 MILLION THROUGH 2022

* COMPANY EXTENDS CASH RUNWAY INTO 2022

* HAVE PRIORITIZED CORE FOUR PROGRAMS TO DRIVE IDE-CEL LAUNCH AND THREE FILINGS IN 2021

* ANNOUNCED AGREEMENT WITH FDA ON CLINICAL DATA PACKAGE REQUIRED TO SUPPORT A BLA SUBMISSION FOR LENTIGLOBIN

* LENTIGLOBIN CLINICAL DATA WILL BE BASED ON DATA FROM PORTION OF PATIENTS IN HGB-206 STUDY GROUP C THAT HAVE ALREADY BEEN TREATED

* PLANNED SUBMISSION WILL BE BASED ON AN ANALYSIS USING COMPLETE RESOLUTION OF SEVERE VOES AS PRIMARY ENDPOINT

* GLOBIN RESPONSE WILL BE USED AS A KEY SECONDARY ENDPOINT FOR LENTIGLOBIN STUDY

* ANTICIPATES ADDITIONAL GUIDANCE FROM FDA REGARDING COMMERCIAL MANUFACTURING PROCESS

* TO SEEK ACCELERATED APPROVAL, EXPECTS TO SUBMIT BLA FOR SICKLE CELL DISEASE IN 2H 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below